

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Amanta Healthcare Limited
8th Floor, Shaligram Corporates, C.J. Marg,
Ambli, Ahmedabad, 380058
Gujarat, India.

1. We have reviewed the unaudited financial results of Amanta Healthcare Limited (the "Company") for the quarter ended June 30, 2025, which are included in the accompanying 'Statement of Unaudited Financial Results for the quarter ended June 30, 2025' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. Attention is drawn to the fact that the financial results for the corresponding period for quarter ended June 30, 2024 and previous quarter ended March 31, 2025, as reported in the Statement have been approved by the Company's Board of Directors, but have not been subjected to review as the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company from the quarter ended June 30, 2025.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Price Waterhouse Chartered Accountants LLP, 17th Floor, Shapath V, Opp. Karnavati Club, S G Highway
Ahmedabad - 380 051, Gujarat, India
T: +91 (79) 69247156

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP Identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Amanta Healthcare Limited

Review Report for the unaudited financial results for the quarter ended June 30, 2025

Page 2 of 2

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP

Firm Registration Number: 012754N/N500016



Devang Mehta

Partner


Membership Number: 118785

UDIN: 25118785BMLBJJ6175

Place: Mumbai

Date: September 26, 2025

AMANTA HEALTHCARE LIMITED					
Registered Office: 8Th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: U24139GJ1994PLC023944. Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in					
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025					
Sr.no.	Particulars	For the quarter ended			(₹ in lakhs)
					For the year ended
		30.06.2025 Un-audited	31.03.2025 Un-audited Refer note 2 and 3	30.06.2024 Un-audited Refer note 3	31.03.2025 Audited
I	Income				
	Revenue from operations	6,530.71	7,206.28	6,809.65	27,470.82
	Other income	96.09	16.20	14.57	138.52
	Total income	6,626.80	7,222.48	6,824.22	27,609.34
II	Expenses				
	Cost of material consumed	2,383.11	2,573.80	2,265.29	10,126.14
	Purchase of stock-in-trade	308.49	448.44	128.30	1,232.04
	Changes in inventories of finished goods, work-in-process and stock-in-trade	(879.20)	(575.02)	14.06	(1,952.65)
	Employee benefits expense	1,014.72	930.89	892.39	3,633.97
	Finance costs (Refer note 6)	628.69	628.11	944.66	2,794.79
	Depreciation and amortisation expense	464.09	469.41	459.97	1,839.89
	Other expenses	2,214.25	1,931.82	2,169.96	8,464.47
	Total expenses	6,134.15	6,407.45	6,874.63	26,138.65
III	Profit / (Loss) before tax (I - II)	492.65	815.03	(50.41)	1,470.69
IV	Tax expense				
	- Current Tax	165.19	184.74	-	362.49
	- Tax adjustment in respect of earlier year	-	(3.27)	-	(3.27)
	- Deferred Tax	(23.26)	37.63	(14.22)	61.40
	Total tax expenses	141.93	219.10	(14.22)	420.62
V	Profit / (Loss) for the period/year (III - IV)	350.72	595.93	(36.19)	1,050.07
VI	Other comprehensive income				
	Items that will not be reclassified to profit and loss				
	Remeasurement (loss) on the defined benefit plans	(13.41)	(20.86)	(13.17)	(53.62)
	Tax relating to remeasurement (loss) of the defined benefit plans	3.37	5.20	3.31	13.50
	Other comprehensive income (net of tax)	(10.04)	(15.46)	(9.86)	(40.12)
VII	Total comprehensive income (V+VI)	340.68	580.47	(46.05)	1,009.95
	Paid up equity share capital (Face value of Rs. 10/- each)	288.29	282.70	282.70	282.70
	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				6,755.89
	Earnings / (Loss) per share (of Rs. 10/- each) (not annualised)				
	Basic and Diluted (Rs.)	1.22	2.11	(0.13)	3.71



Notes:

- 1 The above financial results are prepared in compliance with Indian Accounting Standard ("Ind AS") as notified under section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015], as amended. The above financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on September 26, 2025.
- 2 Figures for the quarter ended March 31, 2025 are the balancing figures between audited figures for the full financial year ended March 31, 2025 and the unaudited year to date figures upto the third quarter of the said financial year ended March 31, 2025.
- 3 The figures for the corresponding quarter ended June 30, 2024 and previous quarter ended March 31, 2025 as reported in these unaudited financial results have been approved by the Company's Board of Directors but have not been subjected to review since the requirement of submission of quarterly financial results is applicable on listing of equity shares of the Company, which was from the quarter ended June 30, 2025. These figures are furnished by the management of the Company and were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on September 26, 2025.
- 4 The Company operates only in one business segment i.e. Manufacturing and sale of pharmaceutical products including contract manufacturing services provided to customer which constitutes single reportable segment in accordance with the requirements of Ind AS 108 "Operating Segments".
- 5 Subsequent to the quarter ended June 30, 2025, the Company has completed its initial public offer (IPO) of fresh issue of 10,000,000 equity shares of face value of Rs. 10 each at an issue price of Rs. 126 per share. The company will provide an update on the utilization of IPO proceeds towards the objects of the fresh issue effective next reporting period based on actual utilization of the funds pursuant to the IPO. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on September 09, 2025. Accordingly, these Unaudited Financial Results for the quarter ended June 30, 2025 are drawn up for the first-time in accordance with the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 6 The finance costs for the quarter ended June 30, 2024 and year ended March 31, 2025 includes Rs. 309.73 lakhs, being cost of derecognition of financial liability consequent to the early redemption of non-convertible debentures.

For and on behalf of Board of Directors



Bhavesh Patel
Chairman and Managing Director
DIN: 00085505

Place: Ahmedabad
Date: September 26, 2025

